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Abstract
Splenomegaly is one of the major clini-
cal manifestations of primary myelofibrosis
and is common also in other chronic
Philadelphia-negative myeloproliferative
neoplasms, causing symptoms and signs
and affecting quality of life of patients diag-
nosed with these diseases. We aimed to
study the impact that such alteration has on
thrombotic risk and on the survival of
patients with essential thrombocythemia
and patients with Polycythemia Vera (PV).
We studied the relationship between
splenomegaly (and its grade), thrombosis
and survival in 238 patients with et and 165
patients with PV followed at our center
between January 1997 and May 2019.
Introduction
The 2016 revision of the WHO
Classification of Tumors of Hematopoietic
and Lymphoid Tissues includes new criteria
for the diagnosis of Philadelphia-negative
myeloproliferative neoplasms (MPNs).
This revision includes Polycythemia Vera
(PV), Essential Thrombocythemia (ET),
and Primary Myelofibrosis (PMF), distin-
guished in overt and prefibrotic PMF.1
Splenomegaly is one of the major clini-
cal manifestations of PMF. Progressive
splenomegaly is significantly associated
with debilitating symptoms, such as early
satiety, abdominal pain, inactivity and
fatigue and may cause portal hypertension
and progression of cytopenias due to
splenic sequestration.2 The symptoms
linked to splenomegaly are associated with
its grade, but it may also be asymptomatic.
In one study, palpable splenomegaly was
observed in 80% of the asymptomatic
patients and about 10% of the patients with
PMF showed severe symptomatic
splenomegaly when diagnosed with PMF.3
The role of splenomegaly on quality of life
and on prognosis in patients with PMF is
fairly well known,4 instead the impact of
splenomegaly in essential thrombocythemia
and polycythemia vera is less investigated.
A mild to moderate spleen enlargement
is present in about 5-20% of ET patients at
diagnosis. Notwithstanding the relatively
common occurrence of this feature, the
prognosis of patients with spleen enlarge-
ment in ET is still unclear.5 PV is a chronic
clonal myeloproliferative neoplasm charac-
terized by increased red-cell mass; elevated
white cell and platelet counts are also com-
monly observed in PV. PV patients have an
increased risk of thrombotic and cardiovas-
cular events and a burden of symptoms that
often includes pruritus, fatigue, and night
sweats.6 In a single center study with 587
patients diagnosed with PV, 155 of 506 with
available data (31%) had palpable
splenomegaly at diagnosis and it was asso-
ciated with a higher risk of developing
venous thrombosis during follow-up.7
Splenomegaly often develops at disease
progression in approximately 30-40% of
patients with PV.8,9
Despite the clinical relevance, increased
spleen size has not been proven as a signif-
icant prognostic factor in the elaboration of
major prognostic models commonly used to
estimate survival, including International
Prognostic Scoring System (IPSS),
Dynamic IPSS (DIPSS), Dynamic IPSS
plus (SIPSS-plus), MF Secondary to
PV/ET-Prognostic Model (MYSEC-PM)
and Mutation-enhanced IPSS70 (MIPSS-
70) in patients with MF, in risk stratification
for survival in patients with PV and ET,10-14
and in traditional stratification for throm-
botic risk for ET and PV,15 in International
Prognostic score of thrombosis (IPSET-
thrombosis, and in revised international
prognostic scoring system for essential
thrombocythemia.16,17
In relation to the frequency and clinical
relevance of splenomegaly in patients with
ET or PV, we aimed to study the impact that
such alteration has on thrombotic risk and
on the survival of these patients.
Materials and Methods
From January 1997 to May 2019, 238
consecutive patients with diagnosis of ET
and 165 patients with PV were followed at
our center. Diagnosis were all made
according to WHO criteria used in the
respective period. The frequency of
splenomegaly at diagnosis was calculated
considering it positive if minimum longitu-
dinal diameter was 15 cm at echotomogra-
phy of computed tomography and was
evaluated in groups of patients with diag-
nosis of PMF, PV and ET. Clinical features,
driver-gene mutational status, age and sex
were collected for all the patients with ET
and PV. The frequency of thrombosis or
cardiovascular events in the groups with
and without splenomegaly and the number
of deaths in the two groups were studied
and survival was estimated using the
Kaplan and Meier method. Comparison
between frequencies is performed with chi-
square test, comparison between medians
with the Kruskal-Wallis test, while compar-
ison between survivals using the log-rank
test.
Results
In our study, 238 patients with ET and
165 with PV were followed along more than
22 years at our institution, with a median
follow-up of 45.96 months (1.5-316.2) for
ET patients and 58.42 months (1.2-298.39)
for PV patients. The median age was
respectively 65.92 years (14.56-92.09) and
62.28 (17.4-93.44). They were diagnosed
according to WHO criteria used in the
respective period.
Data on the driver-gene mutational sta-
tus revealed that, between ET patients,
172/238 (72.26%) were JAK2V617F posi-
tive, 23/238 (9.66%) were CALR mutated
and 4/238 (1.68%) were MPL mutated,
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while 39/238 (16.38%) were triple-nega-
tive; among PV patients, 156/165 (94.54%)
were JAK2V617F positive, 5/165 (3,03%)
harbored mutation on JAK2 exon 12 and
4/165 (2,42%) were negative for JAK2
mutations; 
According to diagnosis subgroups,
splenomegaly was present respectively in
15,54% of patients with ET and in 38.18%
of PV patients. Table 1 shows gender and
median age in patients with or without
splenomegaly distinguished by type of
MPNs. Our data show the presence of
splenomegaly in 24% of males and 11.65%
of females with ET, while showing
splenomegaly in 45.71% of males and in
24.19 of females with PV.
The frequency of thrombosis or cardio-
vascular events appears to be higher in
patients with splenomegaly than in patients
without splenomegaly at diagnosis, both in
patients with ET and in patients with PV. In
fact, they occur in 39.87% of patients with
ET and with splenomegaly towards 24.37%
of patients without splenomegaly (P=0.04).
In patients with PV thrombosis or cardio-
vascular events occurred in 44.44% of
patients with splenomegaly and in 30.39%
of patients without splenomegaly (P=0.02)
In patients with splenomegaly at diag-
nosis we found a higher number of deaths
compared to patients who did not present
splenomegaly both in ET and PV patients,
and respectively 32.43% versus 8.42%
(P=0.0001) and 22.22% versus 7.84%
(P<0.004). Finally, survival in patients pre-
senting with splenomegaly at diagnosis
appears significantly worse, as it can be
seen in Figure 1.
Discussion and Conclusions
Splenomegaly is one of the most com-
mon manifestations among those present at
diagnosis of MPNs. In our experience,
splenomegaly is can be revealed in about
15.54% of patients with ET an 38.18% of
PV patients at diagnosis. Furthermore, our
data show an important correlation with the
thrombotic risk, with the frequency of
deaths and with survival.
Ruxolitinib, an oral JAK1/JAK2
inhibitor, is approved for the treatment of
patients with IPSS intermediate or high-risk
PMF and patients with PV who have had an
inadequate response to or are intolerant to
hydroxyurea. Ruxolitinib has been shown to
be effective in reducing splenomegaly both
in patients with PMF and in patients with
PV,18-20 significantly improving the life
quality of the patients. Current therapies
available for ET do not significantly affect
splenomegaly.
Despite the clinical relevance, increased
spleen size has not been proven as a signif-
icant prognostic factor in major prognostic
models. In accordance with our data and our
experience, we believe that the prognostic
value of splenomegaly is underestimated in
ET and PV and that should be evaluated the
possibility to include it as an item of a prog-
nostic scoring system. Further well-
designed clinical studies are needed to eval-
uate the significance of splenomegaly in ET
and PV patients and its impact on overall
survival and on thrombotic risk. 
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Figure 1. Survival in patients with splenomegaly versus patients without splenomegaly at
diagnosis. In PV patients (A) and ET patients (B).
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